Suppr超能文献

阿法骨化醇单独或联合降钙素对绝经后脊柱病女性骨质疏松性椎体骨折发生率的影响。

Effects of alfacalcidol alone or in combination with elcatonin on incidence of osteoporotic vertebral fractures in postmenopausal women with spondylosis.

作者信息

Miyakoshi Naohisa, Shimada Yoichi, Ando Shigeru, Minato Takashi, Itoi Eiji

机构信息

Department of Orthopedic Surgery, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.

出版信息

J Bone Miner Metab. 2006;24(6):491-7. doi: 10.1007/s00774-006-0713-0.

Abstract

Osteoporosis and spondylosis often occur simultaneously. However, there are no previous reports about the effects of osteoporosis medication on incidence of vertebral fractures in people with spondylosis. In this study, we conducted a retrospective investigation of the effects of alfacalcidol alone or in combination with elcatonin on incidence of osteoporotic vertebral fractures in women with spondylosis. The present subjects were 101 postmenopausal women with osteoporosis aged >60 years, divided into three groups: D group (n = 45), treated for >5 years with alfacalcidol; D+ECT group (n = 26), treated for >5 years with alfacalcidol plus elcatonin; control group (n = 30), who received no medications for >5 years. Over the 5-year treatment period, bone mineral density (BMD) of the lumbar spine and proximal femur did not significantly change in the D and D+ECT groups, but they significantly decreased in the control group (P < 0.05). The number of incident vertebral fractures per patient was significantly higher in the control group (2.9) than in the D group (1.2) and D+ECT group (1.5) (P < 0.01). There was no significant difference in BMD or incident vertebral fractures between the D and D+ECT groups. In all three groups, the number of incident vertebral fractures positively correlated with the number of prevalent vertebral fractures (0.303 </= r </= 0.434), and negatively correlated with baseline BMD (-0.703 </= r </= -0.326) and the osteophyte score representing the degree of spondylosis (-0.769 </= r </= -0.365). Further multiple regression analysis revealed that the medication (D or D+ECT, P < 0.001) and the osteophyte score (P < 0.001) were the most significant contributors for the number of incident vertebral fractures. In conclusion, elcatonin had no additive effects on BMD or prevention of vertebral fractures in postmenopausal women receiving alfacalcidol. Presence of spondylosis (indicated by a high osteophyte score) appears to have an effect on prevention of vertebral fractures.

摘要

骨质疏松症和脊椎病常同时发生。然而,此前尚无关于骨质疏松症药物对脊椎病患者椎体骨折发生率影响的报道。在本研究中,我们对阿法骨化醇单独使用或与降钙素联合使用对患有脊椎病的女性骨质疏松性椎体骨折发生率的影响进行了回顾性调查。本研究对象为101名年龄>60岁的绝经后骨质疏松症女性,分为三组:D组(n = 45),接受阿法骨化醇治疗>5年;D + ECT组(n = 26),接受阿法骨化醇加降钙素治疗>5年;对照组(n = 30),5年以上未接受任何药物治疗。在5年的治疗期内,D组和D + ECT组腰椎和股骨近端的骨密度(BMD)无显著变化,但对照组显著降低(P < 0.05)。对照组患者的椎体骨折发生率(2.9)显著高于D组(1.2)和D + ECT组(1.5)(P < 0.01)。D组和D + ECT组之间的骨密度或椎体骨折发生率无显著差异。在所有三组中,椎体骨折发生率与既往椎体骨折数量呈正相关(0.303 ≤ r ≤ 0.434),与基线骨密度(-0.703 ≤ r ≤ -0.326)以及代表脊椎病程度的骨赘评分呈负相关(-0.769 ≤ r ≤ -0.365)。进一步的多元回归分析显示,药物治疗(D组或D + ECT组,P < 0.001)和骨赘评分(P < 0.001)是椎体骨折发生率的最显著影响因素。总之,降钙素对接受阿法骨化醇治疗的绝经后女性的骨密度或椎体骨折预防无附加作用。脊椎病的存在(以高骨赘评分表示)似乎对椎体骨折的预防有影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验